A randomized trial of cisplatin plus paclitaxel versus cisplatin plus teniposide in advanced non-small cell lung cancer

Giaccone, Giuseppe; Splinter, Ted A.W.; Postmus, P.E.; Díaz-Puente, M. T.; Zandwijk, Nico van; Scagliotti, Giorgio V.; Ardizzoni, Andrea; Meerbeeck, Jan Van; Debruyne, Channa; Sahmoud, Tarek

doi:10.1016/s0169-5002(97)83958-x

Cited by 13 publications

(18 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The combination of cisplatin and vinblastine was chosen as induction chemotherapy for our programme in order to be consistent with the CALGB regimen from which our chemoradiation programme was derived. However, the use of this regimen is no longer justified at the present time given the availability of less toxic and more active last generation chemotherapy regimens (Giaccone et al, 1998).…”

Section: Discussionmentioning

confidence: 99%

Induction chemotherapy followed by concurrent standard radiotherapy and daily low-dose cisplatin in locally advanced non-small-cell lung cancer

et al. 1999

View full text Add to dashboard Cite

Both induction chemotherapy and concurrent low-dose cisplatin have been shown to improve results of thoracic irradiation in the treatment of locally advanced non-small-cell lung cancer (NSCLC). This phase II study was designed to investigate activity and feasibility of a novel chemoradiation regimen consisting of induction chemotherapy followed by standard radiotherapy and concurrent daily low-dose cisplatin. Previously untreated patients with histologically/cytologically proven unresectable stage IIIA/B NSCLC were eligible. Induction chemotherapy consisted of vinblastine 5 mg m −2 intravenously (i.v.) on days 1, 8, 15, 22 and 29, and cisplatin 100 mg m −2 i.v. on days 1 and 22 followed by continuous radiotherapy (60 Gy in 30 fractions) given concurrently with daily cisplatin at a dose of 5 mg m −2 i.v. Thirty-two patients were enrolled. Major toxicity during induction chemotherapy was haematological: grade III–IV leukopenia was observed in 31% and grade II anaemia in 16% of the patients. The most common severe toxicity during concurrent chemoradiation consisted of grade III leukopenia (21% of the patients); grade III oesophagitis occurred in only two patients and pulmonary toxicity in one patient who died of this complication. Eighteen of 32 patients (56%, 95% CI 38–73%) had a major response (11 partial response, seven complete response). With a median follow-up of 38.4 months, the median survival was 12.5 months and the actuarial survival rates at 1, 2 and 3 years were 52%, 26% and 19% respectively. The median event-free survival was 8.3 months with a probability of 40%, 23% and 20% at 1, 2 and 3 years respectively. Induction chemotherapy followed by concurrent daily low-dose cisplatin and thoracic irradiation, in patients with locally advanced NSCLC, is active and feasible with minimal non-haematological toxicity. Long-term survival results are promising and appear to be similar to those of more toxic chemoradiation regimens, warranting further testing of this novel chemoradiation strategy. © 1999 Cancer Research Campaign

show abstract

Section: Discussionmentioning

confidence: 99%

Induction chemotherapy followed by concurrent standard radiotherapy and daily low-dose cisplatin in locally advanced non-small-cell lung cancer

et al. 1999

View full text Add to dashboard Cite

show abstract

“…Trial 1 compared gemcitabine+cisplatin and paclitaxel+gemcitabine to the standard arm paclitaxel+cisplatin, enrolled 480 patients, and used the QLQ-C30 version 3 [18]. Trial 2 compared two cisplatin-based combination chemotherapies, enrolled 332 patients, and used QLQ-C30 version 1 [19]. These two versions of the QLQ-C30 differ only in the response options for the items in the physical and role functioning domains.…”

Section: The Eortc Qlq-c30mentioning

confidence: 99%

Minimal important differences for interpreting health-related quality of life scores from the EORTC QLQ-C30 in lung cancer patients participating in randomized controlled trials

Maringwa

Quinten

King

et al. 2010

Support Care Cancer

148

113

View full text Add to dashboard Cite

Background The aim of this study was to determine the smallest changes in health-related quality of life (HRQOL) scores in a subset of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire core 30 (EORTC QLQ-C30) scales, which could be considered as clinically meaningful in patients with non-small-cell lung cancer (NSCLC).Methods WHO performance status (PS) and weight change were used as clinical anchors to determine minimal important differences (MIDs) in HRQOL change scores (range, 0-100) in the EORTC QLQ-C30 scales. Selected distribution-based methods were used for comparison. Findings In a pooled dataset of 812 NSCLC patients undergoing treatment, the values determined to represent the MID depended on whether patients were improving or

show abstract

“…With combination chemotherapy, such as platinum/etoposide or cyclophosphamide/doxorubicin/etoposide, objective response rates of 20-90% are observed, with a median survival of ,10 months. However, the majority of patients will experience tumour recurrence after successful therapy [2][3][4]. The prognosis with second-line treatment was analysed by HUISMAN et al [5] from 21 published phase II studies, including 1,749 patients showing response rates of 20%.…”

mentioning

confidence: 99%

Efficacy of a toxicity-adjusted topotecan therapy in recurrent small cell lung cancer

Huber¹,

Reck²,

Gosse³

et al. 2006

Eur Respir J

View full text Add to dashboard Cite

The present prospective multicentre trial investigated whether topotecan, given at a starting dose of 1.25 mg?m -2 with individual dose adjustment, can improve safety in patients with relapsed/refractory small cell lung cancer without loss of efficacy.Patients received topotecan intravenously on days 1-5, every 21 days, for up to six courses. In the absence of relevant haematotoxicities, topotecan was increased to 1.5 mg?m -2 and reduced to 1.0 mg?m -2 in case of severe haematotoxicities.Of 170 recruited patients, 73.2% had stage IV disease and 63.4% had platinum-containing pretreatment. Patients received a total of 521 courses. In 72.6% of those courses, the dose remained at 1.25 mg?m -2 ; in 9.1% it was reduced and in 18.3% it increased. Overall response rate was 14.1% including one complete response; 28.8% had stable disease. Median duration of response was 13.6 weeks and median survival was 23.4 weeks. Clinical benefit was obvious for sensitive as well as for refractory patients. Haematotoxicity of grade 3 or 4 was clearly lower compared with the standard dose of 1.5 mg?m , but with reduced toxicity. Since patients with recurrent small cell lung cancer have a poor prognosis, they benefit especially from good tolerability.

show abstract

A randomized trial of cisplatin plus paclitaxel versus cisplatin plus teniposide in advanced non-small cell lung cancer

Cited by 13 publications

References 0 publications

Induction chemotherapy followed by concurrent standard radiotherapy and daily low-dose cisplatin in locally advanced non-small-cell lung cancer

Induction chemotherapy followed by concurrent standard radiotherapy and daily low-dose cisplatin in locally advanced non-small-cell lung cancer

Minimal important differences for interpreting health-related quality of life scores from the EORTC QLQ-C30 in lung cancer patients participating in randomized controlled trials

Efficacy of a toxicity-adjusted topotecan therapy in recurrent small cell lung cancer

Contact Info

Product

Resources

About